|Bid||9.24 x 1200|
|Ask||9.28 x 800|
|Day's Range||8.80 - 9.39|
|52 Week Range||4.45 - 16.60|
|Beta (5Y Monthly)||1.79|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 18, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.63|
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Alan List, M.D. has been appointed as the Company’s Chief Medical Officer and a member of the senior leadership team at Precision BioSciences. Dr. List is a world-renowned hematologist with extensive academic and clinical experience in the research and development of hematology and oncology products. He has led clinical development programs for multiple FDA-approved drugs to treat hematologic malignancies, including myelodysplastic syndromes, acute leukemia, multiple myeloma, and lymphoma.
Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced it has entered into a Program Purchase Agreement to reacquire all global development and commercialization rights for all CAR T partnered programs covered under its Development and Commercial License Agreement with Servier. This includes its two clinical stage CD19-targeting allogeneic CAR T candidates, PBCAR0191 and PBCAR19B stealth cell, as well as four additional product targets.
Stanley R. Frankel, M.D. has been appointed to the Board of Directors for Precision BioSciences.